Skip to main content

Table 1 Patient characteristics

From: Ex vivo tissue slice culture system to measure drug-response rates of hepatic metastatic colorectal cancer

  Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 Patient 7 Patient 8 Patient 9
Initial Diagnosis June 2018 March 2014 July 2017 February 2017 May 2017 June 2016 May 2013 March 2013 August 2016
Primary
 localization rectum rectum rectum rectum caecum rectum rectum rectum CUP/iCRC
 date resection June 2019 Mar 2014 Oct 2017 June 2017 May 2017 Nov 2016 June 2013 Mar 2013 n.a.
 pTNM pT3 pN1b pM1a (HEP) ypT2 pN0
cM0
ypT3
pN0
cM0
ypT2
ypN1a
cM0
pT3
pN1a
cM0
ypT4b
ypN1b
cM0
pT4b
pN1a
pM1a(HEP)
pT3
pN0
cM0
n.a.
 L/V/Pn L1, V1, Pn0, L0, V0, Pn0 L0, V0, Pn0 L0, V0, Pn0 L0, V1, Pn0 L1, V1, Pn1 V0, L1, Pn1 L1, V0, Pn0 n.a.
 UICC-stage IVA I II IIIA IIIB IIIC IVA IVA n.a.
Hepatic Metastasis
 date resection Nov 2018 May 2018 July 2018 Aug 2018 Aug 2018 Sep 2018 Aug 2017 Aug 2017 July 2017
 synchronous - 0, metachronous - 1 0 1 1 1 1 1 0 1 n.a.
Molecular biology
 KRAS WT mutation G12D mutation G12A mutation G13D WT WT WT WT WT
 NRAS WT WT WT WT WT WT WT mutation G13R “c37G > C” WT
 BRAF WT WT WT WT WT WT WT WT WT
 MS-stability MSS MSS MSS MSS MSS MSS MSS MSS MSS
Systemic therapy* yes yes yes yes no yes yes no yes
Checkpoint Inhibition
 PDL-1 IC% 50 23 13 21 16 25 5 6 51
 PDL-1 TC% 0.1 0.5 0.1 2.5 0.5 0.2 0 0 2
 PDL-1 CPS 50.1 23.5 13.1 23.5 16.5 25.2 5 6 53
 PD1 IC% 36 25 29 20 41 31 35 21 34
Death no no no no no no no no no
Recurrence** Jan 2019 (PUL) no no no no no no no Aug 2017 (THO)
Feb 2018 (OSS)
May 2018 (HEP)
  1. CUP/iCRC = Cancer of unknown Primary, immunophenotypically colorectal carcinoma; MS-stability = microsatellite stability; MSS = microsatellite stable, WT = wild type, Jan = January, Feb = February, Mar = March, Aug = August, Oct = October, Nov = November, THO = thorax, OSS = osseous, HEP = hepatic * details of systemic therapy in Additional file 2: Table S6), ** recurrence after resection of analyzed hepatic metastasis